Market move - Design Therapeutics, trading under the ticker DSGN, saw its stock rise 27% on Monday after the company disclosed four-week results from the RESTORE-FA trial of DT-216P2 in patients with Friedreich ataxia.
Data overview - According to the company announcement, DT-216P2 produced dose-dependent improvements across several clinical measures and led to increases in endogenous frataxin (FXN) mRNA and protein following four weeks of intravenous administration. The company characterized the medicine as generally well-tolerated in this period.
Trial design and patient exposure - The RESTORE-FA Phase 1/2 study had 16 patients who completed four weeks of treatment with weekly intravenous DT-216P2 as of May 17. Patients were enrolled across four dose cohorts: 0.1, 0.3, 0.6, and 1 mpk.
Clinical signals at the highest dose - At the 1 mpk dose level, patients registered mean gains from baseline of 6.4 points on the modified Friedreich's Ataxia Rating Scale and 2.7 points on the Upright Stability Score. These measurements reflect changes observed after the four-week dosing period.
Patient-reported outcomes - The treatment also generated changes exceeding five points on the PROMIS Fatigue Scale - a patient-reported measure of fatigue - both at the end of the four-week dosing window and at the two-week follow-up after the final dose. The company highlighted that these changes surpass the commonly cited three-point threshold for what is considered a minimal important change in fatigue.
Biomarker responses - Whole blood FXN mRNA levels rose by 65% from baseline at the 1 mpk dose after four weeks of treatment. Dose-dependent increases in endogenous FXN were reported across FXN mRNA and protein assays in whole blood, and increases in FXN mRNA were also measured in affected muscle tissue.
Safety observations - No serious adverse events or treatment discontinuations were reported during the four-week period. All adverse events observed were classified as mild or moderate. The announcement noted that adverse events deemed possibly or probably related to DT-216P2 and occurring in more than one patient included mild to moderate transient alanine transaminase (ALT) elevations in three patients.
Next steps - Based on the four-week dataset, Design Therapeutics said it intends to pursue a registrational path for DT-216P2. The company plans to provide an update on its development and regulatory strategy in the fourth quarter of 2026.
Context and implications - The data package described by the company includes concordant signals across clinical scales, patient-reported fatigue, and molecular biomarkers in blood and muscle. The firms stated intention to pursue a registrational path signals a forward-looking development plan, with a formal update slated for Q4 2026.